The AMNOG early benefit assessment process in Germany is now over three years old and as tweaks are made to regulations and manufacturers gain more familiarity with the process we look at what can be learned from its oncology drug benefit assessments. Read more here. (Source: Christine Henry, PMLiVE).
Health Outcomes, Market Access, and HEOR Global News Resources and Jobs.
